Myeloproliferative and Myelodysplastic Neoplasms: The Past, Present, and Future

Myeloproliferative and Myelodysplastic Neoplasms: The Past, Present, and Future is organized by United States and Canadian Academy of Pathology (USCAP) and will be held from May 06 - 08, 2024 at USCAP Interactive Center, Palm Springs, California, United States of America.

Course Description:
In the era of the rapid development of new diagnostic modalities and novel targeted treatment options, a comprehensive diagnostic approach to myelodysplastic and myeloproliferative neoplasms becomes ever more critical. However, the rapidly evolving scientific and technological discoveries that have been continuously incorporated into the classification of myelodysplastic and/or myeloproliferative neoplasms significantly increase already complex hematopathology practice. (Hemato)pathologists are currently facing the following challenges:

• How to stay abreast of this avalanche of data?
• How to incorporate the data into my day-to-day practice?
• What testing should I order to correctly classify myelodysplastic and myeloproliferative neoplasms?
• How should my diagnosis be worded in the face of two new classifications of hematologic neoplasms (5th edition WHO and 2022 International Consensus Classifications).

This course, led by four experienced academic hematopathologists practicing at four large cancer centers, will answer all of these questions (and more) by reviewing cases of myeloid neoplasms with myelodysplastic and myeloproliferative features. Join us on the exciting journey from the past to the present and into the future!

Course Objectives:
• Become familiar with the changes to classification of myelodysplastic and myeloproliferative neoplasms and overlap myelodysplastic/myeloproliferative neoplasms.
• Identify critical ancillary testing needed for accurate classification, as informed by the clinical scenario or morphologic findings.
• Recognize morphologic and immunophenotypic correlates of underlying genetic lesions in MDS/MPN and related neoplasms.
• Generate a comprehensive (and comprehensible), clinically relevant, integrated pathology report that includes the most updated classification systems.